Gastroenterology-focused Dr. Reddy's Laboratories was victim of a cyberattack, Pharmaceutical Technology reported Oct. 23.
The pharmaceutical company isolated its data centers and temporarily closed some production facilities after being made aware of the attack. The company's centers in the United Kingdom, Brazil, India, Russia and the U.S. were all affected.
The company didn't reveal details about the attack, but Mukesh Rathi, the company's CIO, said, "We do not foresee any major impact on our operations due to this incident."
Dr. Reddy's is a pharmaceutical company focused on gastroenterology, oncology, pain management and cardiology. It is also conducting a phase 2/3 trial of the Sputnik V COVID-19 vaccine.